Novo Nordisk launches reformulated Ozempic pill in the US
Updated
Updated · Medical News Today · May 5
Novo Nordisk launches reformulated Ozempic pill in the US
11 articles · Updated · Medical News Today · May 5
The oral semaglutide tablet became available from 4 May for adults with type 2 diabetes through more than 70,000 US pharmacies, select telehealth providers and mail-order services.
Novo Nordisk said the smaller pill has the same efficacy and safety as Rybelsus, but with greater bioavailability, and comes in 1.5mg, 4mg and 9mg doses replacing 3mg, 7mg and 14mg.
Insured patients may pay $25 for up to three months, while self-pay prices range from $149 to $299 monthly; the drug is also approved to reduce major cardiovascular events in higher-risk adults.
Can Ozempic's brand power win against a rival pill with superior results and no food restrictions?
What are the hidden health risks of the new absorption-enhancing technology inside every Ozempic pill?
As millions adopt this pill, how will it permanently reshape America's grocery stores and restaurant industry?
Novo Nordisk’s New Oral Ozempic Pill: A Game-Changer for Type 2 Diabetes with Cardiovascular Protection and Improved Accessibility
Overview
On May 4, 2026, Novo Nordisk launched a reformulated oral Ozempic pill in the US, replacing Rybelsus and consolidating both oral and injectable semaglutide treatments under the trusted Ozempic brand. The new pill is smaller and easier to swallow, offering patients a convenient alternative that addresses injection aversion. Clinically, it reduces major cardiovascular events by 14% in high-risk type 2 diabetes patients, thanks to benefits like weight loss and improved blood pressure. Alongside the recent approval of the Wegovy pill for weight management, this launch supports a growing shift toward oral GLP-1 therapies driven by patient preference and strategic pricing to improve access.